United States: FDA Finalizes Guidance Documents On Biosimilars

Six years after legislation was adopted creating a new pathway for the approval of biological products that are biosimilar to existing FDA-approved biologics, the Food and Drug Administration (FDA) continues to issue guidance to clarify its interpretation of the law.

The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) created an abbreviated licensure pathway within the Public Health Service Act (PHS Act) for biological products that are biosimilar to or interchangeable with an FDA-licensed biological product. The BPCI Act essentially created a pathway similar to an Abbreviated New Drug Application, which is used to approve generic drugs, that applies to biologics.

In a series of three final guidance documents issued in late April 2015, the FDA seeks to explain its interpretation of assorted issues concerning the BPCI Act. Those issues include scientific considerations of establishing biosimilarity, quality considerations demonstrating biosimilarity of a therapeutic protein product, and other issues concerning biosimilarity, and requirements for submitting a biologic license application (BLA). Draft versions of these guidance documents were issued in February 2012. The FDA has been seeking input on the BPCI Act since shortly after its enactment; in November 2010, the FDA held a public hearing and established a public docket to solicit input on issues related to implementing the BPCI Act.

Interested persons may submit comments regarding these guidance documents either at http://www.regulations.gov or to the Division of Dockets Management.

Scientific Considerations

The guidance document titled Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, Guidance for Industry intends to assist sponsors in demonstrating biosimilarity between a therapeutic protein product (i.e., the proposed product) and a reference product through the abbreviated licensure pathway created under Section 351(k) of the PHS Act. As an initial matter, the guidance points out that sponsors should be aware of the complexities of protein products and take this into consideration when designing a development program to demonstrate biosimilarity. The guidance then addresses an approach to demonstrating biosimilarity and how the FDA will evaluate that demonstration.

The FDA recommends a stepwise approach to obtain the data and information necessary to support the demonstration of biosimilarity. Using the stepwise approach will allow a sponsor to evaluate uncertainties about the biosimilarity of the proposed product and identify additional steps necessary to address that uncertainty. The FDA lays out a model of the stepwise approach starting with extensive structural and functional characterization which should serve as the foundation for the development program. The guidance also recommends that sponsors consider animal studies, their role in assessing toxicity, and in some cases bolstering support for the biosimilarity demonstration. The guidance also provides information on generic scientific principles for demonstrating biosimilarity, including structural analysis, functional assays, animal data, and clinical studies.

The guidance indicates that when the FDA evaluates the sponsor's demonstration, it will use the totality-of-the-evidence approach when considering the information submitted in the biosimilar application. The FDA will consider the proposed product's characterization, nonclinical evaluation, immunogenicity data, comparative clinical study data, etc. The FDA plans to use a risk-based approach in its evaluation, which will allow for minor structural or formula differences in the proposed product and the reference but still lead to a finding of biosimilarity.

Finally, the guidance addresses post-marketing safety considerations. The guidance indicates that post-marketing safety monitoring should focus on any particular safety or effectiveness issues associated with the reference product or the proposed product. Monitoring should also be designed to differentiate between adverse events associated with the reference product and the proposed product. The FDA may require post-marketing safety studies to evaluate certain safety risks. Because of the complexity and uniqueness of these products, the guidance encourages consultation with the FDA throughout the development process.

Quality Considerations

The guidance document titled Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product deals with the technical aspects of "chemistry, manufacturing, and controls" (CMC) information for a proposed biosimilar application. This guidance intends to provide sponsors with an overview of analytical factors that are relevant to determining whether a proposed product and the reference product are highly similar for the purpose of submitting a marketing application through the abbreviated licensure pathway under section 351(k) of the PHS Act. While the 351(k) pathway applies generally to biological products, this guidance focuses specifically on therapeutic protein products.

This guidance finalizes the draft guidance issued by the FDA in February 2012. In response to comments made on the draft guidance, the final guidance provides further clarification on general principles on topics including the use of comparative analytical data to provide the foundation for a biosimilar development program, the timing of submission of analytical similarity data, the appropriate number of lots needed, and the type of bridging data needed when sponsors use a non-U.S.-licensed comparator product in certain studies.

Additionally, this guidance describes key factors for consideration when assessing whether a proposed product and the reference product are highly similar, including (1) Expression System; (2) Manufacturing Process; (3) Assessment of Physiochemical Properties; (4) Functional Activities; (5) Receptor Binding and Immunochemical Properties; (6) Impurities; (7) Reference Product and Reference Standards; (8) Finished Drug Product; and (9) Stability.

Q&A

The guidance document titled Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, Guidance for Industry answers questions posed to the FDA about the FDA's interpretation of certain statutory requirements added by the BPCI Act. The questions reflect comments submitted to the public docket, and the FDA used the question and answer format in an effort to promote transparency. The FDA plans to update the guidance document to include additional questions and answers in the future.

The questions and answers cover three broad categories: (1) biosimilarity and interchangeability; (2) provisions related to the requirement to submit a BLA for a biological product; and (3) exclusivity.

The bulk of the guidance addresses issues concerning biosimilarity and interchangeability. It clarifies that a biosimilar's application need not exactly mirror all aspects of the reference product. For example, a biosimilar product can have a formulation and a delivery device or container closure system different from the reference product. The application must demonstrate the product is highly similar to the reference product, and that the differing delivery device or container closure system is compatible for use with the final formulation. The FDA also states that a biosimilar product can obtain a license for fewer than all presentations (e.g., strengths or delivery devices or container closure systems) for which the reference product is licensed. An applicant also need not seek a license for all the conditions of use for which the reference product is licensed.

On the issue of demonstrating that a proposed injectable biosimilar product has the same "strength" as the reference product, the FDA explains that the biosimilar product generally must have the same total content and concentration of drug substance as the reference product. However, "for certain complex biological products, a modified approach may be needed."

The BPCI Act amends the definition of "biological product" to include a "protein (except any chemically synthesized polypeptide)," and the guidance document answers the question of how the FDA interprets this definition. The FDA provides a definition for both "protein" – any alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size – and "chemically synthesized polypeptide" – any alpha amino acid polymer that is made entirely by chemical synthesis and is less than 100 amino acids in size.

Finally, the guidance addresses issues of exclusivity. The BPCI Act provides various exclusivity periods, including for reference products and for the first product determined to be interchangeable with a reference product. The FDA answered the question of how a prospective biosimilar applicant can determine if there is unexpired orphan exclusivity for an indication for which the reference product is licensed. The guidance points to the FDA's website, which contains a searchable database for orphan designated and/or approved products and indications. The FDA clarifies that it will not approve a subsequent application for the "same drug" for the indication during the seven-year period of orphan exclusivity, except as otherwise provided in the Federal Food, Drug, and Cosmetic Act, and 21 C.F.R. part 316.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions